Petros Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Fady Boctor

Algemeen directeur

US$528.2k

Totale compensatie

Percentage CEO-salaris	60.74%
Dienstverband CEO	6.4yrs
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Analyseartikel • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...

Recent updates

Analyseartikel • Nov 13

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Key Insights Petros Pharmaceuticals to hold its Annual General Meeting on 20th of November Total pay for CEO Fady...

Seeking Alpha • Aug 15

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Petros Pharmaceuticals press release (NASDAQ:PTPI): Q2 GAAP EPS of -$0.10. Revenue of $6.6M (+0.9% Y/Y).

Seeking Alpha • Jul 28

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Private investment group Henry Crown and Company (HCC) will acquire men's health firm Petros Pharmaceuticals (NASDAQ:PTPI) for $3.25 per share in an all-cash transaction for a total equity value of about $67.2M, the companies said on Thursday. The deal value of $3.25 per share represents a 306.25% premium to PTPI's last closing price of $0.80. PTPI shares zoomed on the announcement, more than tripling in value to $2.63. As per the deal, CVF LLC, an affiliate managing HCC's healthcare investments, will acquire all the outstanding shares of PTPI, which will become a privately-owned company at the close of the transaction. PTPI's board has unanimously approved the merger. HCC expects to finance the deal with existing cash on hand. The companies expect the merger to close by early 2023. The merger also includes the acquisition of PTPI's assets including erectile dysfunction (ED) drug Stendra, a treatment candidate for Peyronie's disease called H100 and a line of medical devices for the treatment of ED.

Seeking Alpha • Dec 07

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Petros Pharmaceuticals is developing complementary men’s health therapeutics. The Company’s target lead indications are erectile dysfunction and Peyronie’s disease. Petros recently announced a $10 million public offering of its common stock for $3 per share.

Analyse CEO-vergoeding

Hoe is Fady Boctor's beloning veranderd ten opzichte van Petros Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	-US$41m
Dec 31 2025	US$528k	US$321k	-US$50m
Sep 30 2025	n/a	n/a	-US$68m
Jun 30 2025	n/a	n/a	-US$70m
Mar 31 2025	n/a	n/a	-US$18m
Dec 31 2024	US$740k	US$333k	-US$13m
Sep 30 2024	n/a	n/a	-US$15m
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$875k	US$350k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$682k	US$350k	-US$20m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$1m	US$350k	-US$9m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$468k	US$276k	-US$21m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$29m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$340k	US$208k	-US$33m

Compensatie versus markt: De totale vergoeding ($USD 528.20K ) Fady } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 643.41K ).

Compensatie versus inkomsten: De vergoeding van Fady is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Fady Boctor (48 yo)

6.4yrs

Tenure

US$528,204

Compensatie

Mr. Fady Boctor, MBA, has been the President and Chief Commercial Officer of Petros Pharmaceuticals, Inc. since 2020. Mr. Boctor has experience in the pharmaceutical industry, across a wide array of functi...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joshua Silverman	Executive Chairman of the Board	5.5yrs	US$792.25k	15.62% $ 39.3k
Wayne Walker	Independent Director	5.5yrs	US$140.65k	1.49% $ 3.8k
Bruce Bernstein	Independent Director	5.5yrs	US$278.80k	6.68% $ 16.8k

5.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PTPI wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/28 16:03
Aandelenkoers aan het einde van de dag	2026/06/26 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Petros Pharmaceuticals, Inc. wordt gevolgd door 1 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Nazibur Rahman	Maxim Group

Petros Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Petros Pharmaceuticals, Inc. Announces Principal Financial Officer Changes, Effective June 18, 2026

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Insufficient new directors

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Recent updates

Petros Pharmaceuticals, Inc. Announces Principal Financial Officer Changes, Effective June 18, 2026

Petros Pharmaceuticals, Inc. announced delayed annual 10-K filing

Petros Pharmaceuticals, Inc. Announces Notice of Common Stock Delisting from Nasdaq

Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from S&P TMI Index

Petros Pharmaceuticals, Inc.(OTCPK:PTPI) dropped from NASDAQ Composite Index

Petros Pharmaceuticals Receives a Letter from the Nasdaq Hearings Panel

New major risk - Revenue and earnings growth

First quarter 2025 earnings released: US$8.46 loss per share (vs US$42.19 loss in 1Q 2024)

Petros Pharmaceuticals, Inc. Announces Nasdaq Non-Compliance Update

Petros Pharmaceuticals, Inc. Announces Nasdaq Non-Compliance Update

New major risk - Negative shareholders equity

Full year 2024 earnings released: US$3.34 loss per share (vs US$6.35 loss in FY 2023)

New major risk - Financial position

Petros Pharmaceuticals, Inc. Announces Proprietary Technology Addressing the Rx-To-OTC Switch Self-Care Market Valued at over $38 Billion Annual

New major risk - Share price stability

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil)

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes

Analyse CEO-vergoeding

CEO